Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Randomised Double-Blind Placebo-Controlled Study of Pirfenidone in Idiopathic Pulmonary Fibrosis
2006-000138-11Phase 3Completed
- Sponsor
- InterMune
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Pirfenidone 2403 mg/day with Placebo (2 arms). Primary endpoint: Change in percent predicted forced vital capacity (FVC) at week 60. Started Feb 2006; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2006-000138-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000138-11.